More Articles

Biocon/Mylan gain global rights to adalimumab biosimilar Hulio Biosimilars/General | Posted 31/05/2019

India-based biologicals specialist Biocon and US-based partner Mylan announced on 7 May 2019 that they have gained the global rights to the adalimumab biosimilar Hulio.

Teva launches generic testosterone gel and overactive bladder treatment in the US Generics/News | Posted 31/05/2019

In April 2019, Israeli generics giant Teva Pharmaceutical Industries (Teva) announced the launch of generic versions of AndroGel (testosterone gel) 1.62% CIII and VESIcare (solifenacin succinate) t...

GaBI Journal is the number one journal publishing on biosimilars Biosimilars/Research | Posted 24/05/2019

The first ever global bibliometric analysis on biosimilars finds that GaBI Journal is the number one journal publishing on biosimilars. The study also shows that research on biosimilars is increasi...

The level of biosimilars competition in Europe varies Reports | Posted 24/05/2019

Patient use of biologicals has generally increased following the introduction of biosimilars. Despite this, levels of competition in Europe are variable across molecules and countries, see Table 1,...

Stakeholders question FDA’s guidance on naming biologicals Guidelines | Posted 24/05/2019

In March 2019, the US Food and Drug Administration (FDA) issued a new draft guidance document concerning non-proprietary name suffixes for biological products [1]. Many stakeholders comments on the...

New biosimilar guide for pharmacists in Australia Policies & Legislation | Posted 24/05/2019

During the Generic and Biosimilar Medicines Association’s (GBMA) Biosimilar Week, Federal Minister for Health, Greg Hunt, introduced Biosimilar Week 2019 along with the launch of the Biosimilar Hub...

Recommendations published by Canadian breast cancer advocacy group Biosimilars/General | Posted 24/05/2019

In April 2019, an advocacy group for patients with breast cancer in Canada – the Canadian Breast Cancer Network (CBCN) - published recommendations related to use of biosimilars in a white paper, en...

Russian approval for non-originator eculizumab Biosimilars/News | Posted 24/05/2019

Russian biotechnology company Generium and Swiss-based cell-line producer Selexis announced on 9 April 2019 that the Russian Ministry of Health had approved their eculizumab non-originator biologic...